354 related articles for article (PubMed ID: 16273638)
41. Fas ligand and Fas receptor are coexpressed in normal human esophageal epithelium: a potential mechanism of apoptotic epithelial turnover.
Bennett MW; O'Connell J; O'Sullivan GC; Roche D; Brady C; Collins JK; Shanahan F
Dis Esophagus; 1999; 12(2):90-8. PubMed ID: 10466040
[TBL] [Abstract][Full Text] [Related]
42. Fas counterattack in cholangiocarcinoma: a mechanism for immune evasion in human hilar cholangiocarcinomas.
Li ZY; Zou SQ
World J Gastroenterol; 2001 Dec; 7(6):860-3. PubMed ID: 11854917
[TBL] [Abstract][Full Text] [Related]
43. Cells behaving badly: a theoretical model for the Fas/FasL system in tumour immunology.
Webb SD; Sherratt JA; Fish RG
Math Biosci; 2002; 179(2):113-29. PubMed ID: 12208611
[TBL] [Abstract][Full Text] [Related]
44. [Expression and function of apoptosis-related genes Bcl-2/Bax and Fas/Fas L in the course of stress ulcer].
Liu J; Li ZS; Wan XJ; Wang W
Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(6):504-9. PubMed ID: 12887767
[TBL] [Abstract][Full Text] [Related]
45. Epithelial ovarian cancer cells secrete functional Fas ligand.
Abrahams VM; Straszewski SL; Kamsteeg M; Hanczaruk B; Schwartz PE; Rutherford TJ; Mor G
Cancer Res; 2003 Sep; 63(17):5573-81. PubMed ID: 14500397
[TBL] [Abstract][Full Text] [Related]
46. Human pancreatic cancer cells express non-functional Fas receptors and counterattack lymphocytes by expressing Fas ligand; a potential mechanism for immune escape.
Elnemr A; Ohta T; Yachie A; Kayahara M; Kitagawa H; Ninomiya I; Fushida S; Fujimura T; Nishimura G; Shimizu K; Miwa K
Int J Oncol; 2001 Jan; 18(1):33-9. PubMed ID: 11115536
[TBL] [Abstract][Full Text] [Related]
47. The Fas/Fas ligand system is involved in the pathogenesis of autoimmune myocarditis in rats.
Ishiyama S; Hiroe M; Nishikawa T; Shimojo T; Abe S; Fujisaki H; Ito H; Yamakawa K; Kobayashi N; Kasajima T; Marumo F
J Immunol; 1998 Nov; 161(9):4695-701. PubMed ID: 9794399
[TBL] [Abstract][Full Text] [Related]
48. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis.
Ungefroren H; Voss M; Jansen M; Roeder C; Henne-Bruns D; Kremer B; Kalthoff H
Cancer Res; 1998 Apr; 58(8):1741-9. PubMed ID: 9563493
[TBL] [Abstract][Full Text] [Related]
49. THP-1 monocytic leukemia cells express Fas ligand constitutively and kill Fas-positive Jurkat cells.
Bremner TA; Chatterjee D; Han Z; Tsan MF; Wyche JH
Leuk Res; 1999 Oct; 23(10):865-70. PubMed ID: 10573130
[TBL] [Abstract][Full Text] [Related]
50. Attack the tumor counterattack-c-FLIP expression in Jurkat-T-cells protects against apoptosis induced by coculture with SW620 colorectal adenocarcinoma cells.
Steiert AE; Sendler D; Burke WF; Choi CY; Reimers K; Vogt PM
J Surg Res; 2012 Jul; 176(1):133-40. PubMed ID: 21944480
[TBL] [Abstract][Full Text] [Related]
51. Close association between Fas ligand (FasL; CD95L)-positive tumor-associated macrophages and apoptotic cancer cells along invasive margin of colorectal carcinoma: a proposal on tumor-host interactions.
Sugita J; Ohtani H; Mizoi T; Saito K; Shiiba K; Sasaki I; Matsuno S; Yagita H; Miyazawa M; Nagura H
Jpn J Cancer Res; 2002 Mar; 93(3):320-8. PubMed ID: 11927015
[TBL] [Abstract][Full Text] [Related]
52. Human chorionic gonadotropin contributes to maternal immunotolerance and endometrial apoptosis by regulating Fas-Fas ligand system.
Kayisli UA; Selam B; Guzeloglu-Kayisli O; Demir R; Arici A
J Immunol; 2003 Sep; 171(5):2305-13. PubMed ID: 12928375
[TBL] [Abstract][Full Text] [Related]
53. Expression of Fas-Fas ligand in murine testis.
Xu JP; Li X; Mori E; Guo MW; Matsuda I; Takaichi H; Amano T; Mori T
Am J Reprod Immunol; 1999 Dec; 42(6):381-8. PubMed ID: 10622469
[TBL] [Abstract][Full Text] [Related]
54. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes.
Gastman BR; Atarshi Y; Reichert TE; Saito T; Balkir L; Rabinowich H; Whiteside TL
Cancer Res; 1999 Oct; 59(20):5356-64. PubMed ID: 10537320
[TBL] [Abstract][Full Text] [Related]
55. Fas ligand is expressed in normal breast epithelial cells and is frequently up-regulated in breast cancer.
Müllauer L; Mosberger I; Grusch M; Rudas M; Chott A
J Pathol; 2000 Jan; 190(1):20-30. PubMed ID: 10640988
[TBL] [Abstract][Full Text] [Related]
56. Expression of functional Fas ligand in choriocarcinoma.
Hammer A; Hartmann M; Sedlmayr P; Walcher W; Kohnen G; Dohr G
Am J Reprod Immunol; 2002 Oct; 48(4):226-34. PubMed ID: 12516633
[TBL] [Abstract][Full Text] [Related]
57. Association between up-regulation of Fas ligand expression and apoptosis of tumor-infiltrating lymphocytes in human breast cancer.
Cheng B
J Huazhong Univ Sci Technolog Med Sci; 2006; 26(5):573-5. PubMed ID: 17219972
[TBL] [Abstract][Full Text] [Related]
58. Fas (APO-1/CD95) ligand and Fas expression in renal cell carcinomas: correlation with the prognostic factors.
Kim YS; Kim KH; Choi JA; Lee JH; Kim HK; Won NH; Kim I
Arch Pathol Lab Med; 2000 May; 124(5):687-93. PubMed ID: 10782148
[TBL] [Abstract][Full Text] [Related]
59. The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy.
Kim R; Emi M; Tanabe K; Uchida Y; Toge T
Cancer; 2004 Jun; 100(11):2281-91. PubMed ID: 15160330
[TBL] [Abstract][Full Text] [Related]
60. Expression of Fas (CD95/APO-1) ligand by human breast cancers: significance for tumor immune privilege.
O'Connell J; Bennett MW; O'Sullivan GC; O'Callaghan J; Collins JK; Shanahan F
Clin Diagn Lab Immunol; 1999 Jul; 6(4):457-63. PubMed ID: 10391843
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
